Features of NSAIDs' use in pandemic. Gastroenterologist's view
https://doi.org/10.33667/2078-5631-2021-6-32-34
Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are drugs used to treat acute and chronic pain associated primarily with inflammatory changes. This group of drugs is widely used in neurology, rheumatology, traumatology, etc. The main mechanism of action of the drugs is associated with the effect on cyclooxygenase-2 (COX-2) and blockade of the synthesis of pro-inflammatory prostaglandins (PG), as well as the effect on COX-1 and suppression of the synthesis of cytoprotective PG, which determines the possibility of side effects from the gastrointestinal tract. In the pandemic, the use of this group of drugs has increased many times over. Features of the clinical course of both the viral infection itself and the use of other drugs leads to a significant change in the pharmacodynamics and pharmacokinetics of NSAIDs, which may lead to the development of undesirable side effects.
About the Author
E. I. Sas
Military Medical Academy n.a. S.M. Kirov
Russian Federation
Russian Federation
Sas Evgeniy I., prof. at 2nd Dept (Advanced Therapy, Therapy for Doctors)
Saint Petersburg
References
1. Каратеев А. Е., Яхно Н. Н., Лазебник Л. Б. и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. Москва, ИМА-Пресс, 2009, 167 с. Karateev A.E., Yakhno N.N., Lazebnik L.B. and others. The use of non-steroidal anti-inflammatory drugs. Clinical guidelines. Moscow, IMA-Press, 2009, 167 p.
2. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020; 181 (2): 281–292. e6. DOI: 10.1016/j.cell.2020.02.058.
3. Boggs W. Liver Injury Common With COVID-19. March 13, 2020 https://www.medscape.com/viewar-ticle/926628
4. Paizis G, Tikellis C, Cooper ME, et al. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut. 2005; 54 (12): 1790–1796. DOI: 10.1136/gut.2004.062398.
5. Albillos A., Lario M., Álvarez-Mon M. Cirrhosisassociated immune dysfunction: Distinctive features and clinical relevance. Journal of Hepatology. 2014; 61: 1385–1396.
6. Maryse Lapeyre-Mestre 1, Sabrina Grolleau, Jean-Louis Montastruc Adverse drug reactions associated with the use of NSAIDs: a case/noncase analysis of spontaneous reports from the French pharmacovigilance database 2002–2006 Fundam Clin Pharmacol. 2013, 27 (2): 223–30. DOI: 10.1111/j.1472–8206.2011.00991.
7. Alaa Rostom, Lawrence Goldkind, Loren Laine. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients Clin Gastroenterol Hepatol. 2005 May; 3 (5): 489–98. DOI: 10.1016/s1542–3565(04)00777–3.
8. Насонов Е.Л. Нестероидные противоспалительные препараты (Перспективы применения в медицине). Москва, Издательство «Анко», 2000; 142 стр. Nasonov E.L. Non-steroidal anti-inflammatory drugs (Prospects for use in medicine). Moscow, Anko Publishing House, 2000; 142 p.
9. Lehmann FS, Beglinger C. Impact of COX-2 inhibitors in common clinical practice a gastroenterologist’s perspective. Curr Top Med Chem. 2005; 5 (5): 449–64.
10. Насонов Е. Л., Лазебник Л. Б., Мареев В. Ю. и сотр. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. Москва, 2006. Nasonov E.L., Lazebnik L.B., Mareev V. Yu. et al. The use of non-steroidal anti-inflammatory drugs. Clinical guidelines. Moscow, 2006.
11. Yun Kit Yeoh, Tao Zuo et all. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut 2021; 70: 698–706. DOI: 10.1136/gutjnl-2020–323020.
12. Hu J, Zhang L, Lin W et al. Review article: Probiotics, prebiotics and dietary approaches during COVID-19 pandemic. Trends Food Sci Technol. 2021; 108: 187–96.
13. Nejadghaderi SA, Nazemalhosseini-Mojarad E, Asadzadeh Aghdaei H. Fecal microbiota transplantation for COVID-19; a potential emerging treatment strategy. Med Hypotheses. 2020; 147: 110476.
14. Rajput S, Paliwal D, Naithani M et al. COVID-19 and Gut Microbiota: A Potential Connection. Indian J Clin Biochem. 2021: 1–12.
15. Jecko Thachil, Ning Tang et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020; 18: 1023–1026.
16. Dominic Wichmann, Jan-Peter Sperhake, Marc Lütgehetmann Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 https://doi.org/10.7326/M20-2003
17. Laine L., et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet, 2007, 369, 465–473.
18. Sooriakumaran P COX-2 inhibitors and the heart: are all coxibs the same? Postgrad Med J. 2006 Apr; 82 (966): 242–245. DOI: 10.1136/pgmj.2005.042234.
19. Søren P. Johnsen, Heidi Larsson, et al. Risk of Hospitalization for Myocardial Infarction Among Users of Rofecoxib, Celecoxib, and Other NSAIDs A Population-Based Case-Control Study Arch Intern Med. 2005; 165 (9): 978–984. DOI: 10.1001/archinte.165.9.978.
20. Malmstrom K., Fricke J., Kotey P., et al. A comparison of rofecoxib versus celecoxib in treating pain after dental surgery: a single center, randomized, double blind, placebo and active comparator controlled, parallel group, single dose study using the dental impaction pain model. Clin Ther. 2002. Vol. 24. P. 1549–1560.
21. Каратеев А.Е., Насонов Е.Л., Корешков Г.Г. НПВП–индуцированная диспепсия: распространенность и возможность медикаментозной коррекции. Науч. практ. ревматол., 2003, 5, 76–78. Karateev A. E., Nasonov E. L., Koreshkov G. G. NSAID-induced dyspepsia: the prevalence and the possibility of drug correction. Sci. practical rheumatol., 2003, 5, 76–78.
22. Lai K., Chu K., Hui W. et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med. 2005, 118 (11), 1271–1278.
Review
For citations:
Sas E.I. Features of NSAIDs' use in pandemic. Gastroenterologist's view. Medical alphabet. 2021;1(6):32-34. (In Russ.) https://doi.org/10.33667/2078-5631-2021-6-32-34
Views:
345
Email this article 